NCT04973527View on ClinicalTrials.gov

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

July 20, 2022

Conditions

T Cell LymphomaT-cell Leukemia

Interventions

DRUG

Efficacy of LCAR-T2C CAR-T cells

CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor

Trial Locations (2)

100000

Beijing Boren Hospital, Beijing

100070

Beijing Boren Hospital, Beijing